Five Prime and bluebird ink CAR T license agreement
CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.—An exclusive license agreement was announced in late May between bluebird bio Inc. and Five Prime Therapeutics Inc. for the research, development and commercialization of chimeric antigen receptor (CAR) T cell therapies using Five Prime's proprietary human antibodies. Per the terms of the agreement, bluebird bio gains exclusive rights to Five Prime's human antibodies to an undisclosed cancer target, and will use its own proprietary lentiviral gene therapy platform and CAR T capabilities to develop therapies against the target. bluebird bio will pay $1.5 million up front to Five Prime, as well as subsequent milestone payments that could total more than $130 million per licensed product if certain development, regulatory and commercial milestones are met. Five Prime also stands to receive tiered royalties on product sales. Conducting and funding clinical development falls to bluebird bio, who will also handle regulatory and commercial activities.